All Comparisons
Retatrutide vs Mazdutide
Research material comparison: purity standards, available formats, molecular data, batch COA documentation, and regulatory status. For in vitro research use only.
Retatrutide: BMazdutide: C
| Attribute | Retatrutide | Mazdutide |
|---|---|---|
| Category | Metabolic / Triple Agonist | Metabolic / Dual GLP-1/Glucagon Agonist |
| Evidence Rating | B — Phase III / NDA Filed | C — Phase I–II Clinical Trials |
| Clinical Status | Phase 3 clinical trials (Eli Lilly TRIUMPH program) | Approved in China: June 2025 for chronic weight management, September 2025 for type 2 diabetes. Phase 2 trials running in the United States. Not approved outside China. |
| Mechanism | Retatrutide simultaneously activates three receptors: GLP-1 (reduces appetite, slows gastric emptying, improves insulin secretion), GIP (enhances insulin sensitivity, glucose control), and glucagon (increases energy expenditure, fat oxidation, thermogenesis). This triple synergy combines reduced cal... | Mazdutide is a fatty acid-acylated peptide that activates both the GLP-1 receptor and the glucagon receptor. The GLP-1 receptor agonism provides glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, and appetite reduction — the same mechanisms as other GLP-1 agonists. Th... |
| Half-Life | ~6 days (allows once-weekly dosing) | Suitable for once-weekly dosing (exact value not fully published) |
| Bioavailability | SC injection | — |
| Molecular Weight | — | ~4233.7 g/mol |
| WADA Status | Not Prohibited | Not Listed |
| Research Half-Life | ~6 days (allows once-weekly dosing) | Suitable for once-weekly dosing (exact value not fully published) |
| Key Use Cases |
|
|
| Safety Concerns |
|
|
| Contraindications |
|
|
| Regulatory (US) | Not FDA-approved. Phase 3 TRIUMPH program ongoing (Eli Lilly). TRIUMPH-4 reported 28.7% body weight loss at 12 mg over 68 weeks. Seven Phase 3 readouts expected in 2026. Regulatory submission expected 2026; approval anticipated 2027-2028. | Not FDA-approved. Eli Lilly sponsored the first-in-human work as LY3305677 and US phase 2 trials are ongoing (NCT06124807, NCT06817356, NCT05623839). Innovent holds China rights and runs the IBI362 programme there. |
Research Material Specifications
Catalog specifications for the corresponding research materials, including batch documentation coverage.
| Specification | Retatrutide | Mazdutide |
|---|---|---|
| Purity Standard | ≥98% | ≥98% |
| CAS Number | 2381089-83-2 | N/A |
| Molecular Formula | C₂₂₅H₃₄₈N₆₀O₆₈S₂ | N/A |
| Available Formats | 20mg, 10mg, 5mg, 30mg | 10mg |
| Batch COAs Published | — | — |
| Stock Status | In stock | Out of stock |
Availability at Volta Peptides
Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.
Explore More
Comparisons
Compare any two peptides side-by-side or browse our curated popular matchups.